The Myelofibrosis drug Inrebic is now available for prescription in general hospitals. According to related industries, Inrevic, a myelofibrosis treatment drug from BMS Pharmaceuticals, passed the Drug Committee (DC) of general hospitals such as SMC and Seoul St. Mary's Hospital. Inrebic received domestic approval in April of last year as 'treatment for splenomegaly or symptoms related to primary myelofibrosis, polycythemia vera, and myelofibrosis after essential thrombocythemia in adult patients previously treated with Jakavi.

After that, he submitted an application for benefits but failed to pass HIRA once in June of last year. After re-applying, it passed both the Cancer Disease Review Committee and